← Back to Search

Cholinesterase Inhibitor

Pyridostigmine Bromide 60 Milligrams (mg) for Hoarseness

Phase 4
Recruiting
Led By Benjamin Rubinstein, MD
Research Sponsored by Eastern Virginia Medical School
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 15 minutes
Awards & highlights

Study Summary

This trial will test if a drug used to treat botulism can also help people with spasmodic dysphonia, a condition that causes involuntary muscle spasms in the voice box.

Eligible Conditions
  • Hoarseness
  • Spastic Dysphonia
  • Spasmodic Dysphonia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~15 minutes
This trial's timeline: 3 weeks for screening, Varies for treatment, and 15 minutes for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Adapted Borg Scale Pre- and Post-Pyridostigmine (Mestinon)
CAPE-V Pre- and Post-Pyridostigmine (Mestinon)
Glottal Function Index Pre- and Post-Pyridostigmine (Mestinon)
+1 more

Trial Design

1Treatment groups
Experimental Treatment
Group I: Pyridostigmine (Mestinon)Experimental Treatment1 Intervention
Pyridostigmine (Mestinon) will be assigned to patients in this arm.

Find a Location

Who is running the clinical trial?

Eastern Virginia Medical SchoolLead Sponsor
68 Previous Clinical Trials
10,393 Total Patients Enrolled
Benjamin Rubinstein, MDPrincipal InvestigatorEastern Virginia Medical School Department of Otolaryngology - Head and Neck Surgery
1 Previous Clinical Trials
40 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Has research been conducted using Pyridostigmine Bromide 60 Milligrams (mg) in the past?

"Currently, there are 4 active clinical trials researching the effects of Pyridostigmine Bromide 60 Milligrams (mg) with none in Phase 3 yet. Most of these studies take place at locations around Nashville, Tennessee but additional sites are being utilized for this research as well."

Answered by AI

Is participation in this research open to volunteers?

"This dysphonia research trial invites 10 participants aged between 21 and 100, regardless of gender. Eligibility is defined by the age range specified above."

Answered by AI

What is the current participant tally for this clinical experiment?

"Affirmative, clinicaltrials.gov provides evidence that this trial is actively recruiting participants since its inception on May 20th 2021 and last update on July 25th 2022. Ten patients are being sought at single medical site for the experiment."

Answered by AI

Has Pyridostigmine Bromide 60 Milligrams (mg) been granted regulatory approval?

"As this is a Phase 4 trial, signifying approval of Pyridostigmine Bromide 60 Milligrams (mg), it has been assessed as having the highest safety rating of 3."

Answered by AI

Is the maximum age limit for this trial set at 40 years or below?

"The cut-off age for individuals to be included in this medical trial is 21 and 100 years old. There are 5 trials specifically designed with participants under 18, while 49 cater to those aged 65 or over."

Answered by AI

Are there still vacancies available for those wishing to participate in this experiment?

"Affirmative. According to the clinicaltrials.gov website, this investigation is still looking for participants after being first posted on May 20th 2021 and last updated on July 25th 2022. 10 people need to be enrolled from 1 medical hub."

Answered by AI

To what medical conditions has Pyridostigmine Bromide 60 Milligrams (mg) been linked with therapeutic benefits?

"Pyridostigmine Bromide 60 Milligrams (mg) can be prescribed for patients struggling with myasthenia gravis, dyschezia, and orthostatic syncope."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine
Benjamin J Rubinstein 2021. "Reversal of Botulinum Neurotoxin Injection Related Dysphonia With Pyridostigmine". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05110417.
~3 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top